RH-PRIVÉ
6.8.2024 14:21:33 CEST | Business Wire | Press release
RH Privé, the leading developer of eco luxury homes on the Costa del Sol, has called on the acclaimed design studio Pininfarina for an exclusive conceptual interior design project. With designs of some of the most iconic sports cars in the automotive history and outstanding architectural projects such as the majestic ICONIC tower in Dubai in his charge, this collaboration aims to further enhance the exclusivity and luxury of the developer's most exclusive development: Carat Sky Villas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806233462/en/
RH Privé unveils two of the world’s most desirable luxury penthouses in Costa del Sol. (Photo: RH Privé)
The penthouses are currently under construction, with delivery expected by the end of the year. In their initial conceptualization, the orientation of each dwelling has played a fundamental role, one ‘floating on the sea’ and the other ‘immersed in the mountains’. Each penthouse has been designed based on a well-differentiated conceptual theme: the first incorporates nautical motifs and the second is inspired by different wood textures, with the intention of integrating nature into the home.
“We are proud to partner with Pininfarina. Our union has allowed us not only to align our values, but also to share experiences, ideas and cultures to result in the project of two exclusive penthouses, unique in Spain”, says Guillermo Rodríguez, CEO of RH Privé.
Carat Sky Villas: a unique experience with sustainability as its core
Both penthouses belong to Carat Sky Villas and are strategically located in the majestic enclave of Reserva del Higuerón, where residents can enjoy the best views of the Mediterranean Sea from the Costa del Sol, as well as large open garden spaces alligned with nature.
Talking about sustainability, Carat Sky Villas stands out for its water saving system based on the reuse of rainwater, decalcification and hydro-efficient taps. It also stands out for its maximum energy efficiency model based on an aerothermal system, individual ventilation and the use of large windows to make the most of natural light. Besides, apart from recycling 70% of the construction materials, RH Privé guarantees respect for the biodiversity of the environment by planting native species in the landscaping design and reforesting the area surrounding the development.
In addition, the homes will benefit from the installation of the latest technology on the market, with a domotic system that allows the control of lighting, access and air conditioning, among many other functions, being able to control everything remotely at any time.
Interior design philosophy and superb amenities
In the heart of these penthouses, borders do not exist, overcoming limits and creating spaces for unique moments. The Sea plays a fundamental role in the design of the spaces. The floors are oriented towards the sea, creating spaces flooded with natural light and offering unforgettable sunsets. Thanks to the large windows, the line between indoors and outdoors is blurred, accentuating the sensation of floating above the sea provided by the infinity pool.
Carat’s welcomes you to the community in which only a select few can live. An excellent wellness area consisting of a salt cave, massage room, hammam, sauna and an indoor heated pool that completes the spa area. For the sportiest Carat offers a luxury gym equipped with Technogym machines, featuring its exclusive Christian Dior equipment. Owners can also enjoy the cinema room, a coworking area with sea views and an outdoor space consisting of an infinity pool, pool bar and solarium. But that's not all, as the promotion will feature a 5-star concierge service, allowing owners to forget about tedious chores.
Download the complete image asset of the interiors here.
About RH Privé
RH Privé is the leading real estate promoter in sustainable luxury development in Spain. After more than 30 years of success in Reserva del Higuerón, in the heart of Costa del Sol, the figures speak for themselves: more than 500 homes delivered, more than 200 under construction and more than 160 recently launched on the market. Always committed to eco-luxury development, each construction enjoys the unique stamp of RH Privé under ESG criteria. With a future full of new projects and ambitions, sustainability plays and will play a key role at the heart of the company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806233462/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom